Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Mackey leads the way ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by Mole101on Jun 07, 2021 12:15pm
255 Views
Post# 33340451

Mackey leads the way ...

Mackey leads the way ...

 

I expect Mackie will be going back to cover PMN and reinstated .80 sp

House  Bought  Sold  Net 
House 083
Mackie
Bought $225,131
Volume 913,500
Average $0.246
Sold 0
Volume 0
Average 0
Net $225,131
Volume 913,500
 
House 007
TD Sec
Bought $167,571
Volume 691,522
Average $0.242
Sold $133,874
Volume 565,450
Average $0.237
Net $33,697
Volume 126,072
 
House 022
Fidelity
Bought $27,399
Volume 116,000
Average $0.236
Sold 0
Volume 0
Average 0
Net $27,399
Volume 116,000
 
House 053
Morgan Stanley
Bought $7,827
Volume 33,000
Average $0.237
Sold 0
Volume 0
Average 0
Net $7,827
Volume 33,000
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities